A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis

Journal of Medicinal Chemistry

Volumn 53, Issue 6, 2010, Pages 2589-2600

  Chen, Zhuo ^a   Liang, Xin ^a   Zhang, Huanying ^a   Xie, Hua ^a,b   Liu, Jianwen ^a   Xu, Yufang ^a   Zhu, Weiping ^a   Wang, Yi ^b   Wang, Xin ^a   Tan, Shaoying ^a   Kuang, Dong ^a   Qian, Xuhong ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 (4 METHYLPIPERAZIN 1 YL)PROPYL] 6 (OCTYLAMINO) 1H BENZO[DE]ISOQUINOLINE 1,3(2H) DIONE; 2 [3 (DIMETHYLAMINO)PROPYL] 6 (METHYLAMINO) 1H BENZO[DE]ISOQUINOLINE 1,3(2H) DIONE; 2 [3 (DIMETHYLAMINO)PROPYL] 6 (OCTYLAMINO) 1H BENZO[DE]ISOQUINOLINE 1,3(2H) DIONE; 2 [3 [2 (DIMETHYLAMINO)ETHYLAMINO]PROPYL] 6 (DODECYLAMINO) 1H BENZO[DE]ISOQUINOLINE 1,3(2H) DIONE; 2 [3 [2 (DIMETHYLAMINO)ETHYLAMINO]PROPYL] 6 (OCTYLAMINO) 1H BENZO[DE]ISOQUINOLINE 1,3(2H) DIONE; 2 DODECYL 6 (OCTYLAMINO) 1H BENZO[DE]ISOQUINOLINE 1,3(2H) DIONE; 2 DODECYL 6 [2 (4 METHYLPIPERAZIN 1 YL)ETHYLAMINO] 1H BENZO[DE]ISOQUINOLINE 1,3(2H) DIONE; 6 (DODECYLAMINO) 2 [3 (4 METHYLPIPERAZIN 1 YL)PROPYL] 1H BENZO[DE]ISOQUINOLINE 1,3(2H) DIONE; 6 [2 (4 METHYLPIPERAZIN 1 YL)ETHYLAMINO] 2 OCTYL 1H BENZO[DE]ISOQUINOLINE 1,3(2H) DIONE; 6 [2 (DIMETHYLAMINO)ETHYLAMINO] 2 DODECYL 1H BENZO[DE]ISOQUINOLINE 1,3(2H) DIONE; 6 [2 [2 (DIMETHYLAMINO)ETHYLAMINO]ETHYLAMINO] 2 DODECYL 1H BENZO[DE]ISOQUINOLINE 1,3(2H) DIONE; 6 [2 [2 (DIMETHYLAMINO)ETHYLAMINO]ETHYLAMINO] 2 OCTYL 1H BENZO[DE]ISOQUINOLINE 1,3(2H) DIONE; AMONAFIDE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; NAPHTHALIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; INTERACTIONS WITH DNA; LYSOSOME MEMBRANE; MEMBRANE PERMEABILITY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL SURVIVAL; CIRCULAR DICHROISM; DNA; DNA TOPOISOMERASES, TYPE II; DRUG DESIGN; HELA CELLS; HL-60 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; INTRACELLULAR MEMBRANES; LYSOSOMES; MODELS, CHEMICAL; MOLECULAR STRUCTURE; NAPHTHALIMIDES; PERMEABILITY; PLASMIDS; SPECTROMETRY, FLUORESCENCE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949868503     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100025u     Document Type: Article

References (69)

1. Sawyers, C. Targeted cancer therapy. Nature 2004, 432 (7015), 294-297.
2. Petrelli, A.; Giordano, S. From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage. Curr. Med. Chem. 2008, 15 (5), 422-432
3. Fu, Z.; Malureanu, L.; Huang, J.; Wang, W.; Li, H.; Van Deursen, J. M.; Tindall, D. J.; Chen, J. Plk1-dependent phosphorylation of FoxM 1 regulates a transcriptional programme required for mitotic progression. Nat. Cell Biol. 2008, 10 (9), 1076-1082.
4. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. Opinion-How many drug targets are there? Nat. Rev. Drug Discov. 2006, 5 (12), 993-996.
5. Szuromi, P.; Vinson, V.; Marshall, E. Rethinking drug discovery-Introduction. Science 2004, 303 (5665), 1795-1795
6. Osterborg, A.; Mellstedt, H.; Keating, M. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Med. Oncol. 2002, 19, S21-S26.
7. Bode, A. M.; Dong, Z. G. Cancer prevention research - Then and now. Nat. Rev. Cancer 2009, 9 (7), 508-516.
8. Zhan, P.; Liu, X. Y. Designed multiple ligands: An emerging antiHIV drug discovery paradigm. Curr. Pharm. Des. 2009, 15 (16), 1893-1917.
9. Van der Schyf, C. J.; Geldenhuys, W. J. Polycyclic compounds: Ideal drug scaffolds for the design of multiple mechanism drugs? Neurotherapeutics 2009, 5 (1), 175-186.
10. Futerman, A. H.; Sussman, J. L.; Horowitz, M.; Silman, I.; Zimran, A. New directions in the treatment of Gaucher disease. Trends Pharmacol. Sci. 2004, 25 (3), 147-151.
11. Schrattenholz, A.; Soskic, V. What does systems biology mean for drug development? Curr. Med. Chem. 2008, 15 (15), 1520-1528.
12. Borisy, A. A.; Elliott, P. J.; Hurst, N. W.; Lee, M. S.; Lehar, J.; Price, E. R.; Serbedzija, G.; Zimmermann, G. R.; Foley, M. A.; Stockwell, B. R.; Keith, C. T. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (13), 7977-7982.
13. Zimmermann, G. R.; Lehar, J.; Keith, C. T. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discov. Today 2007, 12 (1-2), 34-42.
14. Van der Greef, J.; McBurney, R. N. Innovation - Rescuing drug discovery: In vivo systems pathology and systems pharmacology. Nat. Rev. Drug Discov. 2005, 4 (12), 961-967.
15. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48 (21), 6523-6543.
16. Wei, D. G.; Jiang, X. L.; Zhou, L.; Chen, J.; Chen, Z.; He, C.; Yang, K.; Liu, Y.; Pei, J. F.; Lai, L. H. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J. Med. Chem. 2008, 51 (24), 7882-7888.
17. Hopkins, A. L. Network pharmacology: The next paradigm in drug discovery. Nat. Chem. Biol. 2008, 4 (11), 682-690.
18. Kerr, J. F. R.; Wyllie, A. H.; Currie, A. R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26 (4), 239-257.
19. Fischer, U.; Janssen, K.; Schulze-Osthoff, K. Cutting-edge apoptosis-based therapeutics - A panacea for cancer? Biodrugs 2007, 21 (5), 273-297.
20. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267 (5203), 1456-1462.
21. Reed, J. C. Apoptosis-based therapies. Nat. Rev. Drug Discov. 2002, 1 (2), 111-121.
22. Kroemer, G.; Galluzzi, L.; Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007, 87 (1), 99-163.
23. Tian, Z. Y.; Xie, S. Q.; Du, Y. W.; Ma, Y. F.; Zhao, J.; Gao, W. Y.; Wang, C. J. Synthesis, cytotoxicity and apoptosis of naphthalimide polyamine conjugates as antitumor agents. Eur. J. Med. Chem. 2009, 44 (1), 393-399.
24. Okada, H.; Mak, T. W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. Cancer 2004, 4 (8), 592-603.
25. Fadeel, B.; Orrenius, S. Apoptosis: A basic biological phenomenon with wide-ranging implications in human disease. J. Intern. Med. 2005, 258 (6), 479-517.
26. Boya, P.; Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene 2008, 27 (50), 6434-6451.
27. Hoyer-Hansen, M.; Jaattela, M. Autophagy - An emerging target for cancer therapy. Autophagy 2008, 4 (5), 574-580.
28. Gocheva, V.; Zeng, W.; Ke, D. X.; Klimstra, D.; Reinheckel, T.; Peters, C.; Hanahan, D.; Joyce, J. A. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006, 20 (5), 543-556.
29. Fehrenbacher, N.; Jaattela, M. Lysosomes as targets for cancer therapy. Cancer Res. 2005, 65 (8), 2993-2995.
30. Linder, S.; Shoshan, M. C. Lysosomes and endoplasmic reticulum: Targets for improved, selective anticancer therapy. Drug Resist. Updates 2005, 8 (4), 199-204.
31. Roy, D.; Liston, D. R.; Idone, V. J.; Di, A.; Nelson, D. J.; Pujol, C.; Bliska, J. B.; Chakrabarti, S.; Andrews, N. W. A process for controlling intracellular bacterial infections induced by membrane injury. Science 2004, 304 (5616), 1515-1518.
32. Kroemer, G.; Jaattela, M. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 2005, 5 (11), 886-897.
33. Erdal, H.; Berndtsson, M.; Castro, J.; Brunk, U.; Shoshan, M. C.; Linder, S. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (1), 192-197.
34. Groth-Pedersen, L.; Ostenfeld, M. S.; Hoyer-Hansen, M.; Nylandsted, J.; Jaattela, M. Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine. Cancer Res. 2007, 67 (5), 2217-2225.
35. Parry, M. J.; Alakoskela, J. M. I.; Khandelia, H.; Kumar, S. A.; Jaattela, M.; Mahalka, A. K.; Kinnunen, P. K. J. High-affinity small molecule-phospholipid complex formation: Binding of siramesine to phosphatidic acid. J. Am. Chem. Soc. 2008, 130 (39), 12953-12960.
36. Ostenfeld, M. S.; Hoyer-Hansen, M.; Bastholm, L.; Fehrenbacher, N.; Olsen, O. D.; Groth-Pedersen, L.; Puustinen, P.; Kirkegaard-Sorensen, T.; Nylandsted, J.; Farkas, T.; Jaattela, M. Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation. Autophagy 2008, 4 (4), 487-499.
37. Li, W.; Yuan, X. M.; Nordgren, G.; Dalen, H.; Dubowchik, G. M.; Firestone, R. A.; Brunk, U. T. Induction of cell death by the lysosomotropic detergent MSDH. FEBS Lett. 2000, 470 (1), 35-39.
38. Ostenfeld, M. S.; Fehrenbacher, N.; Hoyer-Hansen, M.; Thomsen, C.; Farkas, T.; Jaattela, M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 2005, 65 (19), 8975-8983.
39. Hurley, L. H. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2002, 2 (3), 188-200.
40. Tao, Z. F.; Wang, L.; Stewart, K. D.; Chen, Z. H.; Gu, W.; Bui, M. H.; Merta, P.; Zhang, H. Y.; Kovar, P.; Johnson, E.; Park, C.; Judge, R.; Rosenberg, S.; Sowin, T.; Lin, N. H. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. J. Med. Chem. 2007, 50 (1), 1514-1527.
41. Brana, M. F.; Ramos, A. Naphthalimides as anti-cancer agents: Synthesis and biological activity. Curr. Med. Chem.: Anti-Cancer Agents 2001, 1 (2), 237-255.
42. Ingrassia, L.; Lefranc, F.; Kiss, R.; Mijatovic, T. Naphthalimides and azonafides as promising anti-cancer agents. Curr. Med. Chem. 2009, 16 (10), 1192-1213.
43. Ratain, M. J.; Mick, R.; Berezin, F.; Janisch, L.; Schilsky, R. L.; Vogelzang, N. J.; Lane, L. B. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993, 53 (10), 2304-2308.
44. Brana, M. F.; Cacho, M.; Garcia, M. A.; de Pascual-Teresa, B.; Ramos, A.; Dominguez, M. T.; Pozuelo, J. M.; Abradelo, C.; Rey-Stolle, M. F.; Yuste, M.; Banez-Coronel, M.; Lacal, J. C. New analogues of amonafide and elinafide, containing aromatic heterocycles: Synthesis, antitumor activity, molecular modeling, and DNA binding properties. J. Med. Chem. 2004, 47 (6), 1391-1399.
45. Antonini, I.; Santoni, G.; Lucciarini, R.; Amantini, C.; Sparapani, S.; Magnano, A. Synthesis and biological evaluation of new asymmetrical bisintercalators as potential antitumor drugs. J. Med. Chem. 2006, 49 (24), 7198-7207.
46. Van Quaquebeke, E.; Mahieu, T.; Dumont, P.; Dewelle, J.; Ribaucour, F.; Simon, G.; Sauvage, S.; Gaussin, J. F.; Tuti, J.; El Yazidi, M.; Van Vynckt, F.; Mijatovic, T.; Lefranc, F.; Darro, F.; Kiss, R. 2,2,2-Trichloro-N-({2-[2- (dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro1H-benzo[de]isoquinolin5-yl} carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J. Med. Chem. 2007, 50 (17), 4122-4134.
47. Tumiatti, V.; Milelli, A.; Minarini, A.; Rosini, M.; Bolognesi, M. L.; Micco, M.; Andrisano, V.; Bartolini, M.; Mancini, F.; Recanatini, M.; Cavalli, A.; Melchiorre, C. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer. J. Med. Chem. 2008, 51 (22), 7308-7312.
48. Li, Z. G.; Yang, Q.; Qian, X. H. Novel thiazonaphthalimides as efficient antitumor and DNA photocleaving agents: Effects of intercalation, side chains, and substituent groups. Biorg. Med. Chem. 2005, 13 (16), 4864-4870.
49. Norton, J. T.;Witsch, M. A.; Luong, L.; Kawamura, A.; Ghosh, S.; Stack, M. S.; Sim, E.; Avram, M. J.; Appella, D. H.; Huang, S. Synthesis and anticancer activities of 6-amino amonafide derivatives. Anti-Cancer Drugs 2008, 19 (1), 22-26.
50. Iranpoor, N.; Firouzabadi, H.; Aghapour, G.; Vaezzadeh, A. R. Triphenylphosphine/2,3-dichloro-5,6-dicyanobenzoquinone as a new, selective and neutral system for the facile conversion of alcohols, thiols and selenols to alkyl halides in the presence of halide ions. Tetrahedron 2002, 58 (43), 8689-8693.
51. Xuhong, Q.; Zhenghua, Z.; Kongchang, C. A study on the Ullmann condensation reaction of 4-chloro-1,8-naphthalic anhydride with N,N-dimethylformamide. J. Prakt. Chem./Chem.-Ztg. 1992, 334 (2), 161-164.
52. Ott, I.; Xu, Y. F.; Liu, J. W.; Kokoschka, M.; Harlos, M.; Sheldrick, W. S.; Qian, X. H. Sulfur-substituted naphthalimides as photoactivatable anticancer agents: DNA interaction, fluorescence imaging, and phototoxic effects in cultured tumor cells. Biorg. Med. Chem. 2008, 15(15), 7107-7116.
53. Zhang, Z. C.; Yang, Y. Y.; Zhang, D. N.;Wang, Y. Y.; Qian, X. H.; Liu, F. Y. Acenaphtho[1,2-b]pyrrole derivatives as new family of intercalators: Various DNA binding geometry and interesting antitumor capacity. Biorg. Med. Chem. 2006, 14 (20), 6962-6970.
54. Mizushima, T.; Natori, S.; Sekimizu, K. Relaxation of supercoiled DNA associated with induction of heat shock proteins in Escherichia coli. Mol. Gen. Genet. 1993, 238 (1-2), 1-5.
55. Wang, J. C. Cellular roles of DNA topoisomerases: A molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 5 (6), 430-440.
56. Li, T. K.; Liu, L. F. Tumor cell death induced by topoisomerase-targeting drugs. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 53-77.
57. Larsen, A. K.; Eseargueil, A. E.; Skladanowski, A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther. 2003, 99 (2), 167-181.
58. Zhu, H.; Huang, M.; Yang, F.; Chen, Y.; Miao, Z. H.; Qian, X. H.; Xu, Y. F.; Qin, Y. X.; Luo, H. B.; Shen, X.; Geng, M. Y.; Cai, Y. J.; Ding, J. R16, a novel amonafide analogue, induces apoptosis and G(2)-M arrest via poisoning topoisomerase II. Mol. Cancer Ther. 2007, 5 (2), 484-495.
59. Tanabe, K.; Ikegami, Y.; Ishida, R.; Andoh, T. Inhibition of topoisomerase-II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res. 1991, 51 (18), 4903-4908.
60. Zdolsek, J. M.; Olsson, G. M.; Brunk, U. T. Photooxidative damage to lysosomes of cultured macrophages by acridine orange. Photochem. Photobiol. 1990, 51 (1), 61-116
61. Boya, P.; Andreau, K.; Poncet, D.; Zamzami, N.; Perfettini, J. L.; Metivier, D.; Ojcius, D. M.; Jaattela, M.; Kroemer, G. Lysosomal membrane permeabilization induces cell death in a mitochondriondependent fashion. J. Exp. Med. 2003, 197(10), 1323-1334.
62. Yuan, X. M.; Li, W.; Dalen, H.; Lotem, J.; Kama, R.; Sachs, L.; Brunk, U. T. Lysosomal destabilization in p53-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (9), 6286-6291.
63. Green, D. R.; Reed, J. C. Mitochondria and apoptosis. Science 1998, 281 (5381), 1309-1312.
64. Garrido, C.; Galluzzi, L.; Brunet, M.; Puig, P. E.; Didelot, C.; Kroemer, G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 2006, 13 (9), 1423-1433.
65. Lim, M. L. R.; Chen, B. H.; Beart, P.M.; Nagley, P. Relative timing of redistribution of cytochrome c and Smac/DIABLO from mitochondria during apoptosis assessed by double immunocytochemistry on mammalian cells. Exp. Cell Res. 2006, 312 (1), 1174-1184.
66. Vermes, I.; Haanen, C.; Steffensnakken, H.; Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J. Immunol. Methods 1995, 184 (1), 39-51.
67. Riccardi, C.; Nicoletti, I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 2006, 1, 1458-1461.
68. Zhang, W. T.; Ruan, J. L.; Wu, P. F.; Jiang, F. C.; Zhang, L. N.; Fang, W.; Chen, X. L.; Wang, Y.; Cao, B. S.; Chen, G. Y.; Zhu, Y. J.; Gu, J.; Chen, J. G. Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymer-ases inhibitors. J. Med. Chem. 2009, 52 (2), 718-725.
69. Joo, S. S.; Yoo, Y. M. Melatonin induces apoptotic death in LNCaP cells via p38 and JNK pathways: Therapeutic implications for prostate cancer. J. Pineal Res. 2009, 47 (1), 8-14.